Perineural Versus IV Dexmedetomidine as Adjuvant to Quadratus Lamborum Block for Pediatrics Undergoing Pyeloplasty
Status:
Completed
Trial end date:
2019-08-21
Target enrollment:
Participant gender:
Summary
this prospective parallel group double blinded study will be conducted over 50 pediatric
patients ASA (American Association of Anesthesiologists) I and II between the age of 8-13
years old,who will be scheduled for laparoscopic pyeloplasty.Patients will be randomly
allocated into 2 study groups: Quadratus lamborum dexmedetomidine intravenous group(QD IV
group) and Quadratus lamborum dexmedetomidine perineural group(QD PN group.Patients in both
groups will receive quadratus lamborum block .In QD IV group a bolus of 0.5 ml/Kg bupivacaine
0.25% in addition to 2ml normal saline will be injected then dexmedetomidine.1ml/kg loading
dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end
of surgery. In QD PN, patients will receive perineural dexmedetomidine of 1μ g/kg diluted to
2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion
1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of
surgery.Time to first analgesic requirement ( primary outcome) , Wong-Baker FACES Pain Rating
Scale scores will be recorded at 2, 6, 8,12, 18 and 24h postoperatively, the degree of
sedation will be assessed by Ramsay sedation scores(fig.2)(9) at the same time points,
hemo-dynamics as systolic and diastolic blood pressures and heart rates will be recorded at
PACU discharge then 4 hourly, total dose of morphine consumption, , the length of hospital
stay, incidence of postoperative complications as hypotension, bradycardia, vomiting,
pruritis and respiratory depression